CombiNAber specifications

Information


Unique identifier OMICS_16796
Name CombiNAber
Interface Web user interface
Restrictions to use None
Computer skills Basic
Stability Stable
Maintained Yes

Maintainer


  • person_outline CombiNAber Team <>

Publication for CombiNAber

CombiNAber in publications

 (2)
PMCID: 5854441
PMID: 29505593
DOI: 10.1371/journal.ppat.1006860

[…] used from previous studies [, , , , , ]., we used the previously developed bliss-hill model [] to predict the ic80 and fraction maximum inhibition values for 2 ab combinations, using the web tool, combinaber (https://www.hiv.lanl.gov/content/sequence/combinaber/combinaber.html). the individual ab ic50 and ic80 experimental data was the input, and a target concentration of 5μg/ml of each ab […]

PMCID: 5889116
PMID: 29444432
DOI: 10.1016/j.celrep.2018.01.023

[…] of neutralization, and simultaneous neutralization coverage by both antibodies for two-antibody (ab) combinations using ic50 and ic80 data for individual antibodies, as implemented on the web tool combinaber at the los alamos hiv database (http://www.hiv.lanl.gov/content/sequence/combinaber/combinaber.html). we used the antibodies 3bnc117 and vrc07-523ls (cd4 binding site); cap256-vrc26.25 […]


To access a full list of publications, you will need to upgrade to our premium service.

CombiNAber institution(s)
Theoretical Division, Los Alamos National Laboratory, Los Alamos, NM, USA; Santa Fe Institute, Santa Fe, NM, USA; Division of Medical Virology, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town and NHLS, Cape Town, South Africa; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA; Department of Surgery, Duke University Medical Center, Durham, NC, USA; Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA; University of KwaZulu-Natal, Durban Department of Immunology and Microbial Science, Durban, South Africa; Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa; The Scripps Research Institute, La Jolla, CA, USA; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA; National Institute for Communicable Diseases (NICD), NHLS, University of the Witwatersrand, Johannesburg, South Africa
CombiNAber funding source(s)
This work was supported by the Bill and Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery (CAVD) grant #1032144, and in part from the intramural research program of the Vaccine Research Center (VRC), NIAID, NIH, and by the Center for Nonlinear Studies (CNLS) at Los Alamos National Laboratory.

CombiNAber reviews

star_border star_border star_border star_border star_border
star star star star star

Be the first to review CombiNAber